Silas Inman, Senior Vice President, Content, joined MJH Life Sciences™ in early 2011 as one of the company's first web editors. In this position, he built OncLive.com from a fledgling web platform to a leading source of oncology news for community oncologists via in-depth reporting of breaking news from major medical conferences and the launch of OncLive® TV.
Throughout his tenure at MJH, Silas has been accountable for several organic launches of highly successful brands, including Targeted Oncology™ and NeurologyLive®, and for quickly transforming acquisitions into high-functioning business units. Prior to joining MJH, Silas, who attended Eastern Michigan University, was an EMT, frontend web developer, and social media/SEO expert. Follow him on Twitter @SilasInman or email him at sinman@mjhlifesciences.com
Next-Generation BCMA CAR T-cell Therapy Effective for Heavily Pretreated Myeloma
December 3rd 2018The anti-BCMA CAR T cell therapy bb21217 demonstrated an objective response rate of 83.3%, with a very good partial response or better rate of 75% in patients with heavily pretreated relapsed/refractory multiple myeloma.
Read More
Tisagenlecleucel Benefit Sustained in DLBCL Follow-Up
December 2nd 2018Tisagenlecleucel continued to demonstrate durable objective response rates with a median of 19 months of follow-up for patients with relapsed or refractory diffuse large B-cell lymphoma, according to updated findings from the phase II JULIET study.
Read More
Tisagenlecleucel OS, RFS Sustained in Long-Term Follow-Up for Pediatric ALL
December 2nd 2018Treatment with the CD19-targeted CAR T-cell therapy tisagenlecleucel demonstrated sustained rates of relapse-free survival and overall survival at 24 and 18 months for pediatric and young adult patients with relapsed or refractory acute lymphoblastic leukemia.
Read More
CAR T-Cell Therapies Moving to Outpatient Setting
November 8th 2018The high durable response rates seen with CAR T-cell therapies have helped fill a high unmet need for patients with relapsed/refractory diffuse large B-cell lymphoma, with questions remaining on the optimal way to use these agents following the FDA approval of 2 therapies in the past year.
Read More
FDA Delays Decision on Frontline Atezolizumab for NSCLC
September 6th 2018The FDA has extended the review period for a supplemental biologics license application for atezolizumab for use in combination with bevacizumab, carboplatin, and paclitaxel for the first-line treatment of patients with metastatic nonsquamous non–small cell lung cancer.
Read More
Frontline Immunotherapy Poses Fresh Dilemma for Sequencing in NSCLC
July 29th 2018As the checkpoint inhibitors move into the frontline setting for patients with non–small cell lung cancer, the focus has been placed on the duration of therapy and what to do in the second-line setting following progression.
Read More
Immunotherapy Combos Rapidly Evolving for Lung Cancer
July 28th 2018The past year has witnessed an explosion in immunotherapy combinations for patients with lung cancer, accompanied by a growing knowledge of biomarkers such as PD-L1 and tumor mutation burden; however, an exact standard of care remains elusive.
Read More
Palbociclib Misses OS Endpoint in PALOMA-3 Breast Cancer Study
June 25th 2018The combination of palbociclib (Ibrance) and fulvestrant (Faslodex) failed to improve overall survival compared with fulvestrant and placebo in the phase III PALOMA-3 trial for patients with HR-positive, HER2-negative metastatic breast cancer.
Read More
FDA Adds PD-L1 Expression to Frontline Pembrolizumab, Atezolizumab Urothelial Carcinoma Labels
June 21st 2018The FDA has incorporated PD-L1 status into the labels for pembrolizumab (Keytruda) and atezolizumab (Tecentriq) for existing frontline approvals for platinum-ineligible patients with urothelial carcinoma.
Read More
Nivolumab Plus Low-Dose Ipilimumab Shows Durable Responses for PD-L1-Negative, TMB-High NSCLC
June 6th 2018The combination of nivolumab and low-dose ipilimumab reduced the risk of progression or death by 52% compared with standard platinum doublet chemotherapy for patients with metastatic PD-L1–negative, tumor mutation burden-high non–small cell lung cancer.
Read More
Frontline Atezolizumab Regimen Improves Survival for NSCLC
June 5th 2018The combination of atezolizumab, bevacizumab, carboplatin, and paclitaxel educed the risk of death by 22% compared with bevacizumab and chemotherapy in patients with advanced wild-type non-squamous non–small cell lung cancer.
Read More
Rituximab/Lenalidomide Potential Frontline Therapy for Follicular Lymphoma
June 4th 2018Similar efficacy with the combination of rituximab and lenalidomide coupled with a better safety profile compared with rituximab plus chemotherapy may make the chemo-free regimen a new frontline option for patients with previously untreated follicular lymphoma.
Read More
Frontline Ibrutinib/Venetoclax Combo Shows High MRD-Negative Responses for CLL
June 4th 2018The frontline combination of ibrutinib and venetoclax demonstrated a 100% objective response rate for patients with chronic lymphocytic leukemia, with 77% of patients testing negative for minimal residual disease in the peripheral blood after 6 cycles.
Read More